Annual Cash & Cash Equivalents
$153.30 M
+$49.16 M+47.21%
December 31, 2023
Summary
- As of February 7, 2025, PCRX annual cash & cash equivalents is $153.30 million, with the most recent change of +$49.16 million (+47.21%) on December 31, 2023.
- During the last 3 years, PCRX annual cash & cash equivalents has risen by +$53.34 million (+53.36%).
- PCRX annual cash & cash equivalents is now -73.82% below its all-time high of $585.58 million, reached on December 31, 2021.
Performance
PCRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$245.97 M
-$1.09 M-0.44%
September 30, 2024
Summary
- As of February 7, 2025, PCRX quarterly cash and cash equivalents is $245.97 million, with the most recent change of -$1.09 million (-0.44%) on September 30, 2024.
- Over the past year, PCRX quarterly cash and cash equivalents has increased by +$146.85 million (+148.15%).
- PCRX quarterly cash and cash equivalents is now -58.00% below its all-time high of $585.58 million, reached on December 31, 2021.
Performance
PCRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PCRX Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +47.2% | +148.2% |
3 y3 years | +53.4% | +8.5% |
5 y5 years | +15.7% | +8.5% |
PCRX Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -73.8% | +47.2% | -58.0% | +592.0% |
5 y | 5-year | -73.8% | +96.0% | -58.0% | +592.0% |
alltime | all time | -73.8% | +2066.1% | -58.0% | +7170.6% |
Pacira BioSciences Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $245.97 M(-0.4%) |
Jun 2024 | - | $247.05 M(+34.2%) |
Mar 2024 | - | $184.05 M(+20.1%) |
Dec 2023 | $153.30 M(+47.2%) | $153.30 M(+54.7%) |
Sep 2023 | - | $99.12 M(+14.2%) |
Jun 2023 | - | $86.81 M(+144.2%) |
Mar 2023 | - | $35.55 M(-65.9%) |
Dec 2022 | $104.14 M(-82.2%) | $104.14 M(-4.8%) |
Sep 2022 | - | $109.42 M(-10.4%) |
Jun 2022 | - | $122.06 M(-46.2%) |
Mar 2022 | - | $226.75 M(-61.3%) |
Dec 2021 | $585.58 M(+485.8%) | $585.58 M(+336.9%) |
Sep 2021 | - | $134.04 M(+26.7%) |
Jun 2021 | - | $105.77 M(+58.6%) |
Mar 2021 | - | $66.70 M(-33.3%) |
Dec 2020 | $99.96 M(+27.8%) | $99.96 M(-20.2%) |
Sep 2020 | - | $125.24 M(+59.4%) |
Jun 2020 | - | $78.55 M(+43.9%) |
Mar 2020 | - | $54.59 M(-30.2%) |
Dec 2019 | $78.23 M(-41.0%) | $78.23 M(-8.1%) |
Sep 2019 | - | $85.14 M(+42.5%) |
Jun 2019 | - | $59.74 M(-72.2%) |
Mar 2019 | - | $215.04 M(+62.3%) |
Dec 2018 | $132.53 M(+144.8%) | $132.53 M(-42.6%) |
Sep 2018 | - | $230.94 M(+97.6%) |
Jun 2018 | - | $116.87 M(+181.2%) |
Mar 2018 | - | $41.56 M(-23.2%) |
Dec 2017 | $54.13 M | $54.13 M(+106.5%) |
Sep 2017 | - | $26.22 M(-51.3%) |
Jun 2017 | - | $53.81 M(-50.6%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2017 | - | $108.97 M(+203.2%) |
Dec 2016 | $35.94 M(-36.9%) | $35.94 M(+47.1%) |
Sep 2016 | - | $24.44 M(-3.4%) |
Jun 2016 | - | $25.31 M(-27.7%) |
Mar 2016 | - | $35.03 M(-38.5%) |
Dec 2015 | $56.98 M(+51.9%) | $56.98 M(+86.7%) |
Sep 2015 | - | $30.52 M(-6.7%) |
Jun 2015 | - | $32.72 M(-20.0%) |
Mar 2015 | - | $40.90 M(+9.0%) |
Dec 2014 | $37.52 M(+199.8%) | $37.52 M(+111.3%) |
Sep 2014 | - | $17.76 M(-83.6%) |
Jun 2014 | - | $108.20 M(+476.7%) |
Mar 2014 | - | $18.76 M(+49.9%) |
Dec 2013 | $12.52 M(+23.6%) | $12.52 M(+269.9%) |
Sep 2013 | - | $3.38 M(-60.8%) |
Jun 2013 | - | $8.63 M(-67.2%) |
Mar 2013 | - | $26.27 M(+159.5%) |
Dec 2012 | $10.13 M(-78.1%) | $10.13 M(+16.3%) |
Sep 2012 | - | $8.71 M(-59.4%) |
Jun 2012 | - | $21.45 M(-14.9%) |
Mar 2012 | - | $25.21 M(-45.4%) |
Dec 2011 | $46.17 M(+76.7%) | $46.17 M(+181.5%) |
Sep 2011 | - | $16.40 M(-40.2%) |
Jun 2011 | - | $27.45 M(-53.7%) |
Mar 2011 | - | $59.33 M(+127.0%) |
Dec 2010 | $26.13 M(+269.3%) | $26.13 M(+88.7%) |
Sep 2010 | - | $13.85 M(+12.1%) |
Jun 2010 | - | $12.35 M(+74.6%) |
Dec 2009 | $7.08 M(-42.9%) | $7.08 M |
Dec 2008 | $12.39 M | - |
FAQ
- What is Pacira BioSciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Pacira BioSciences?
- What is Pacira BioSciences annual cash & cash equivalents year-on-year change?
- What is Pacira BioSciences quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Pacira BioSciences?
- What is Pacira BioSciences quarterly cash and cash equivalents year-on-year change?
What is Pacira BioSciences annual cash & cash equivalents?
The current annual cash & cash equivalents of PCRX is $153.30 M
What is the all time high annual cash & cash equivalents for Pacira BioSciences?
Pacira BioSciences all-time high annual cash & cash equivalents is $585.58 M
What is Pacira BioSciences annual cash & cash equivalents year-on-year change?
Over the past year, PCRX annual cash & cash equivalents has changed by +$49.16 M (+47.21%)
What is Pacira BioSciences quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PCRX is $245.97 M
What is the all time high quarterly cash and cash equivalents for Pacira BioSciences?
Pacira BioSciences all-time high quarterly cash and cash equivalents is $585.58 M
What is Pacira BioSciences quarterly cash and cash equivalents year-on-year change?
Over the past year, PCRX quarterly cash and cash equivalents has changed by +$146.85 M (+148.15%)